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ABSTRACT
Despite being one of the most common cancers, treatment options for prostate cancer are limited.
Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-
grade next generation sequencing (NGS) in prostate cancer, as well as genomic alterations identified
and their potential actionability. Of 4864 patients from multiple institutions for whom NGS was ordered
by physicians, only 67 (1.4%) had prostate cancer, representing 1/10 the ordering rate for lung cancer.
Prostate cancers harbored 148 unique alterations affecting 63 distinct genes. No two patients had an
identical molecular portfolio. The median number of characterized genomic alterations per patient was 3
(range, 1 to 9). Fifty-six of 67 patients (84%) had ≥ 1 potentially actionable alteration. TMPRSS2 fusions
affected 28.4% of patients. Genomic aberrations were most frequently detected in TP53 (55.2% of
patients), PTEN (29.9%), MYC (17.9%), PIK3CA (13.4%), APC (9.0%), BRCA2 (9.0%), CCND1 (9.0%), and RB1
genes (9.0%). The PI3K (52.2% of patients), WNT (13.5%), DNA repair (17.9%), cell cycle (19.4%), and
MAPK (14.9%) machinery were commonly impacted. A minority of patients harbored BRAF, NTRK, ERBB2,
or mismatch repair gene abnormalities, which are highly druggable in some cancers. Only ~ 10% of
prostate cancer trials (clinicaltrials.gov, year 2017) applied a (non-hormone) biomarker before interven-
tion. In conclusion, though use of clinical-grade NGS is relatively low and only a minority of trials deploy
DNA-based biomarkers, many prostate cancer-associated molecular alterations may be pharmacologi-
cally tractable with genomcially targeted therapy or, in the case of mismatch repair anomalies, with
checkpoint inhibitor immunotherapy.
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Introduction
Prostate cancer is themost common cancer and a leading cause of
death in American men.1 Hormone therapy has been the corner-
stone of treatment for decades.2 Molecular targeted therapy has
been changing the treatment landscape in other malignancies,
such as non-small cell lung, breast, and colorectal cancer.
However, no genomically targeted therapy is approved by the
Food and Drug Administration (FDA) for prostate cancer, and,
historically (September 2011 through September 2014), only
~ 2.0% of prostate cancer clinical trials listed on clinicaltrials.gov
utilized a non-hormone biomarker to match patients with
therapy.2
Genomic profiling of cancer using next-generation sequencing
(NGS) is gaining popularity in the clinical setting.3–8 By sequen-
cing the tumor genome, potential actionable genomic aberrations
can be discovered. Mutation profile can be used as a biomarker to
guide appropriate matched targeted therapy and is also emerging
as a marker for immunotherapy, with specific alterations such as
PDL1 amplification, aberrant mismatch repair genes and high
tumor burden being correlated with responsiveness.9
In order to better understand the landscape of prostate cancer
and the utilization of genomic testing in this population, we
conducted an analysis of prostate cancer tissue referred for next
generation sequencing (NGS) and data interpretation to a Clinical
Laboratory Improvement Amendments (CLIA) certified labora-
tory. Here, we report the comparative frequency of NGS utiliza-
tion, the molecular alterations, and potential actionability in
prostate cancer.
Results
Frequency of testing
A total of 4864 tissue samples were profiled and inter-
preted. Table 1 demonstrates that prostate cancer was sig-
nificantly less frequently profiled than other common
malignancies. Indeed, while only 67 patients with prostate
cancer underwent NGS, this testing was ordered in 673,
474, and 299 patients, respectively, with lung, breast and
colorectal cancer. Amongst genitourinary malignancies,
prostate cancer was the least frequently sequenced cancer
(bladder cancer was tested in 124 cases, and kidney cancer
was sequenced in 121 patients).
Genomic aberrations in prostate cancer
All 67 prostate tumors had at least one genomic aberration
(variants of unknown significance (VUS) were excluded).
The most common aberrations were in the following genes:
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TP53 (55.2% of patients), followed by PTEN (29.9%), MYC
(17.9%), PIK3CA (13.4%), APC (9.0%), BRCA2 (9.0%),
CCND1 (9.0%), and RB1 (9.0%) (Figure 1). A fusion invol-
ving TMPRSS2 was found in 28.4% of patients. The median
number of genomic alterations per patient was 3 (range, 1
to 9) (Figure 2A). Fifty-six of 67 patients (84%) had at least
one potentially actionable alteration (Table 2). The median
number of potentially actionable genes per patient was 2
(range, 0 to 7) (Figure 2B).
Prostate tumors have diverse and unique genomic
portfolios
There were 63 distinct genes that harbored alterations; 73% of
the altered genes (46 of 63) were found in ≤ 3% of patients;
altogether there were 148 distinct alterations. Figure 3 shows
that the molecular alterations in each patient were unique.
Five patients had the same genomic portfolio: two with only
TP53 alterations, and three with TP53 and TMPRSS2 fusions.
However, in each case, the precise loci altered within the
genes was different. Therefore, at the molecular level, no
two patients had an identical molecular portrait.
Diverse pathways are altered in prostate cancer
Signals altered in prostate cancer affected the PI3K/Akt/mTor
axis, and the Wnt, DNA repair, cell cycle, and MAPK path-
ways (Table 2).
PI3K pathway
The PI3K pathway regulates cell proliferation, apoptosis,
growth, and longevity and is frequently altered in many
malignancies10 In prostate cancer, the PI3K pathway aberra-
tions (including alterations in PTEN, PIK3CA, PIK3R1, NF2,
AKT1, and NF1 genes) were found in 37 of 67 patients
(52.2%) with metastatic prostate cancer in our dataset.
Amongst patients with PI3K axis alterations, PTEN was the
most frequently altered gene (29.9% of patients (20/67)),
followed by PIK3CA (13.4%), PIK3R1 (6.0%), NF2 (3.0%),
AKT1 (1.5%), and NF1 (1.5%). Among PTEN aberrations,
loss of PTEN was more frequent (17.9% (12/67)) compared
to mutations (11.9%). Amplification was seen in a subset of
PIK3CA-altered tumors (1.5% of 67 patients).
Wnt pathway
Genomic alterations of the Wnt pathway were previously
reported in 18% of metastatic castrate-resistant prostate
cancer11 In our study, the frequency of Wnt pathway altera-
tions was 13.5%. Recurrent alterations in APC were found in
9.0% of our patient population while mutations in CTNNB1
occurred in 4.5% of our patients.
DNA repair pathway
In our series, the DNA repair pathway was aberrant in 17.9% of
patients. BRCA2 was the most frequently altered (9.0% of indi-
viduals). ATM is known to be recruited and activated by DNA
double strand breaks, and was altered in 3.0% of our patients.
BRCA1 was less frequently mutated (1.5% of patients).
Interestingly, the genes that regulate microsatellite instability,
such asMSH6 andMSH2, were mutated in our study in a small
subset of individuals (3.0% and 1.5%, respectively).
Cell cycle pathway
The loss of RB1 is a common event in prostate cancer, and 9.0%
of patients were found to harbor an aberration in RB. Other
genes that regulate the cell cycle also demonstrated alterations:
CCND1 (9.0% of patients), CDKN2A (6.0%), CDK4 (3.0%),
CDKN1B (1.5%), CDKN2B (3.0%), CCND3 (1.5%), CDK8
(1.5%), and CDKN2C (1.5%). These results imply the impor-
tant involvement of cell cycle regulators in prostate cancer.
MAPK pathway
The MAPK pathway plays a significant role in oncogenesis
and alterations in this pathway are found in many
malignancies12 In total, 14.9% patients with prostate cancer
had aberrations in the MAPK pathway. BRAF was the most
commonly altered gene (6.0% of patients), followed by KRAS
(4.5%), HRAS (3.0%), and RAF1 (3.0%).
Other potentially actionable targets (Figure 1, Table 2)
In addition to the pathways described above, there were other
potentially targetable alterations in very small subgroups. For
example, ErbB2 can be targeted by Her2-directed therapy,
such as trastuzumab, and was amplified in one of our patients
Table 1. Estimated incidence andprevalence of prostate cancer and othermalignancies in theUnited States. Incidence, prevalence, estimated death estimates are based on SEER
database (http://seer.cancer.gov/statfacts), and five year survival rate for stage IV is obtained from Cancer Research UK (http://www.cancerresearchuk.org.).
Disease site
Incidence
in U.S. Prevalence in U.S. 5-year survival for Stage IV Estimated deaths in 2015 in U.S.(%)*
NGS tests performed
N (%)**
All Cancers 1,685,210 14,140,254 NA 595,690 4864
Lung 224,200 415,707 2% 158,080 (27%)* 673 (14%)**
Breast 246,660 3,053,450 15% 40,450 (7%)* 474 (10%)**
Colorectal 134,490 1,177,556 5% 49,190 (8%)* 299 (6%)**
Bladder 76,960 587,426 10% 16,390 (3%)* 124 (3%)**
Kidney 62,700 394,336 5% 14,240 (2%)* 121 (2%)**
Prostate 180,890 2,850,139 30% 26,120 (4%)* 67 (1.4%)**
*Refers to percent of deaths from all cancers. Total deaths = 595,690
** Refers to percent of tests done. Total tests done = 4864
Abbreviations: NA = not available
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(1.5% of the dataset). Other receptor tyrosine kinases, such as
ERBB3, ERBB4, FGFR1, FGFR2, FGFR3, FLT3, KIT, NTRK1,
NTRK3, were also abnormal, albeit often in only one patient.
Although the frequency of each alteration was low, the cumu-
lative frequency was significant–22.4% of patients had at least
one such rare, but possibly druggable abnormality.
Biomarker driven clinical trials for prostate cancer
We searched clinicaltrials.gov for all recruiting prostate cancer
clinical trials noted during a one year period (starting January 1,
2017). Overall, 208 interventional protocols, of which 162 were
therapeutic, were listed. Only 17 (10%) used a non-hormone
biomarker for patient selecton.
Figure 1. Genomic aberrations in prostate cancer. Next-generation sequencing was performed in 67 prostate cancer patient specimens. Bar represents the frequency
of genetic alterations among 67 patients.
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Discussion
Analysis of genomic alterations is now clinically feasible, and
many guidelines have begun to incorporate NGS analysis into
clinical practice.13 Further, the FDA recently approved some
NGS testing, such as the type utilized in the current study.
Our analysis found that NGS was performed infrequently in
prostate cancer. Comparatively, NGS was done in prostate
cancer at only one tenth of the rate in lung cancer and one
sixth of that in breast cancer (Table 1) This low rate of testing
is striking because of the high incidence and prevalence of
prostate cancer, but might be in part attributable to its more
indolent nature. Relatedly, from a historic perspective, very
few therapeutic clinical trials in prostate cancer used a non-
hormone biomarker for patient selection (only 2% of the 357
therapeutic trials on clinicaltrials.gov in the three year period
from September 2011 and September 2014, while 20% of trials
included a targeted (non-hormone modulator) agent2). Our
current analysis shows that only 10% of recruiting prostate
cancer-directed therapeutic trials in 2017 used a non-hor-
mone biomarker for selection of patients. Importantly, pre-
vious meta-analyses have demonstrated that deploying
targeted agents without a biomarker is associated with exceed-
ingly low median response rates (about 5%) and, furthermore,
that overall response rates for therapeutic clinical trials that
lack biomarkers is approximately 10% (regardless of the type
of agent). In contrast, median response rates in clinical trials
enrolling biomarker-selected patient populations for treat-
ment with targeted agents are about 30%.14–16
Our analysis of genomic alterations in prostate cancer
confirmed that TP53 is the most frequently altered gene,
followed by the PI3K pathway-associated genes11,17 (Table 3)
Our study and that of Robinson and colleague11 examined
samples from late-stage disease and found TP53 alterations in
55.2% and 53.3% of patients, respectively, whereas TCGA
analysis17 was conducted using early-stage samples, perhaps
explaining why TCGA found TP53 alterations in only 7.5% of
biopsies. The frequency of TMPRSS2-fusions in our study was
lower than in other studies, perhaps due to small sample size.
Alterations in the PI3K/Akt/mTor pathway occurred in
about half of the patients, with the most frequent abnormal-
ities in PTEN and in PIK3CA genes. Templeton et al. reported
that everolimus, an mTOR inhibitor, resulted in a prostate
specific antigen (PSA) response in 11% of patients with cas-
trate-resistance prostate cancer (CRPC), albeit in a non-bio-
marker-selected population.18 The PSA response correlated
with PTEN deletion status, suggesting a biological rationale
to target genetic aberrations in the PI3K pathway.18 However,
other studies have suggested that single-agent mTOR inhibi-
tors have low rates of activity in advanced cancers, even in the
presence of PI3k/Akt/mTor axis alteration,19–21 while combi-
nation therapy that includes these agents have significantly
better activity in the presence of these aberrations.20
Recent clinical trials demonstrated that DNA-repair path-
way aberrations can be a new treatment target. A phase 2
study of the PARP inhibitor olaparib in patients with CRPC
harboring DNA-repair pathway abnormalities, including
BRCA2 mutation, demonstrated remarkably high response
rates of 88 % in patients with CRPC.22 In our analysis and
in Robinson’s data11(Table 3), BRCA2 was abnormal in 9% to
13% of patients with late-stage disease.
BRAF anomalies were identified in 6% of our study popu-
lation. Anti-BRAF therapy is a standard of care in melanoma,
and can be effective in multiple (but not all) BRAF-mutated
cancers.23,24 The utility of BRAF inhibition is unknown in
prostate cancer.
Systematic treatment for prostate cancer has been focused
on the androgen pathway, with nine androgen antagonists
approved by the FDA for this malignancy. However, our
data suggest that there are multiple other alterations that
merit exploration in prostate cancer. Some of these alterations
may be uncommon, but highly sensitive to targeted agents.-
25,26 For example, some tumors harboring NTRK fusions
respond well to larotrectinib.25
There are several limitations to the current study. They
include the relatively small number of patients studied and the
fact that full genomic sequencing was not performed
However, part of the purpose of the study was to understand
the utilization of clinical-grade NGS (rather than research-
grade NGS such as that in TCGA) in the practice setting. In
addition, the data was de-identified, so it is not known
whether or not the ordering physicians exploited the NGS
results to decide on treatment.
In conclusion, our results demonstrate that patients with
advanced prostate cancer have diverse genomic alterations,
many of which may be pharmacologically tractable. Important
Figure 2. The frequency of genomic alterations per patient and the frequency of actionable genetic aberrations per patient. A. The frequency of genetic alterations
per patient. B. Frequency of theoretically actionable genetic alterations per patient.
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pathways impacted include PI3k/Akt/mTor, MAPK, cell cycle,
DNA repair and WNT. In addition, small numbers of patients
harbor turmors with ERBB2, BRAF and NTRK alterations, all of
which are highly druggable in several other malignancies. ERBB3,
ERBB4, FGFR1, FGFR2, FGFR3, FLT3, KIT aberrations were also
found in somepatients and could also be tractable. Even so, there is
a disproportionately low rate of genomic testing compared to
other common malignancies. Further, there is a paucity of trials
that match targeted agents with genomic alterations in prostate
cancer, with only about 10% of current prostate cancer trials listed
Figure 3. Visualization of genomic alteration patterns in individual patient. Each color represents genomic alterations in each patient. (Green: mutation, Red:
amplification, Blue: loss, Orange: fusion, Purple: structural change, Yellow: indel).
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on clinicaltrials.gov using a non-hormone biomarker before inter-
vention. Of interest, most of our patients had multiple genomic
alterations, which differed from patient to patient. In total, there
were 148 distinct abnormalities involving 63 different genes.
Similar phenomena have been seen in other tumor types as well,
and suggest that individualized combinations of cognate targeted
drugs may be necessary to optimize treatment27-29 Finally, three
patients (4.5%) had an abnormal mismatch repair gene, which has
been associatedwith high tumormutation burden and response to
checkpoint inhibitor immunotherapy in many tumors30,31 Taken
together, these data indicate that more genomically based studies
in prostate cancer are urgently needed.
Table 2. Potentially actionable alterations and examples of targeted agents. The data of 50% inhibitory concentrations (IC50s) is available at http://tanlab.ucdenver.
edu.
Gene
alteration Frequency Examples of therapies Comments
Examples of
References/
protocols
PI3K axis (52.2%)*
PTEN 20/67 (29.9%) Everolimus
Sirolimus
Sirolimus
Sirolimus
Sirolimus
Sirolimus
Everolimus demonstrated PSA response in 11% of non-
biomarker selected prostate cancer patients.
20
PIK3CA 9/67 (13.4%)
PIK3R1 4/67 (6.0%)
NF2 2/67 (3.0%)
AKT1 1/67 (1.5%)
NF1 1/67 (1.5%)
WNT pathway (13.5%)*
APC 6/67 (9.0%) Sulindac
Celecoxib
Sulindac decreased CTNNB1 expression in vivo.
CTNNB1 3/67 (4.5%)
DNA Repair pathway (17.9%)*
BRCA2 6/67 (9.0%) Olaparib (ATM, BRCA)
Cisplatin (BRCA)
Carboplatin(BRCA)
Nivolumab, pembrolizumab, or atezolizumab
(mismatch repair gene defects (MSH6 or MSH2))
Phase 3 study of olaparib demonstrated responses in 88% of
DNA-repair pathway aberrant prostate cancer
NCT01682772
NCT02677038ATM 2/67 (3.0%)
MSH6 2/67 (3.0%)
BRCA1 1/67 (1.5%)
MSH2 1/67 (1.5%)
Cell cycle pathway (19.4%)*
CCND1 6/67 (9.0%) Palbociclib
Palbociclib
Palbociclib
Palbociclib
Phase 2 trial of palbociclib is in progress in biomarker-selected
population.
NCT02905318
CDKN2A 6/67 (9.0%)
CDK4 2/67 (3.0%)
CDKN1B 1/67 (1.5%)
CDK8 1/67 (1.5%) Palbociclib
CDKN2C 1/67 (1.5%) Palbociclib
MAPK pathway (14.9%)*
BRAF 4/67 (6.0%) Vemurafenib
Dabrafenib
Trametinib
Cobimetinib
A study with vemurafenib is in progress in biomarker-selected
prostate cancer population.
NCT02208583
KRAS 3/67 (4.5%) Trametinib Cobimetinib Phase 2 study with trametinib is planned in CRPC patients. NCT02881242
HRAS 2/67 (3.0%) Trametinib Cobimetinib
RAF1 2/67 (3.0%) Trametinib Cobimetinib
Other actionable targets (22.4%)*
ERBB2 1/67 (1.5%) Trastuzumab
Lapatinib
ERBB3 1/67 (1.5%) Pertuzumab
Afatinib
Pertuzumab interferes with dimerization between ERBB2 and
ERBB3ERBB4 1/67 (1.5%)
FGFR1 1/67 (1.5%) Lenvatinib
Lenvatinib
Lenvatinib
Lenvatinib inhibits activity of FGFR 26
FGFR2 1/67 (1.5%)
FGFR4 2/67 (3.0%)
FLT1 1/67 (1.5%) Lenvatinib
FLT3 1/67 (1.5%) Lenvatinib
FLT4 1/67 (1.5%) Lenvatinib
KIT 1/67 (1.5%) Imatinib
NTRK1 2/67 (3.0%) Crizotinib
LOXO-101
25
NCT02576431NTRK3 1/67 (1.5%)
PTCH1 1/67 (1.5%) Vismodegib
Sonidegib
*Some patients had more than one alteration in a pathway; they were counted only once
Abbreviations: CRPC = castrate-resistant prostate cancer; PSA = prostate specific antigen.
Table 3. Comparison of genomic alteration frequencies across different genomic
profiling studies in prostate cancer.
Current report
N = 67 patients
Robinson et al 11
N = 150 patients
TCGA
N = 333 patients
17
Stage Late stage Late stage Early stage
TP53 55.2% 53.3% 7.5%
PTEN 29.9% 40.7% 45.7%
TMPRSS2 translocation 28.4% 56.7% 45.7%
MYC 17.9% 14% 7.5%
PIK3CA 13.4% 5.3% 4.8%
APC 9.0% 8.7% 5.4%
BRCA2 9.0% 13.3% 3.3%
BRAF 6.0% 2.7% 3.9%
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Patients and methods
Patients
We analyzed prostate cancer specimen data submitted to
Foundation Medicine Inc. (Cambridge, MA) (https://www.
foundationmedicine.com/) for genomic sequencing and to
N-of-One Inc. for data interpretation. The diagnosis and the
origin of tissue were provided by ordering physicians from
multiple institutions. The prostate cancer data was derived
from a database of 4864 consecutive Foundation Medicine
samples annotated by N-of-One starting in December 2011.
The study was conducted in accordance with University of
California San Diego Institutional Review Board guidelines
for a de-identified database.
Tissue preparation, genomic sequencing, and
bioinformatic analysis
Samples from formalin-fixed paraffin-embedded tissue were
submitted to a CLIA-certified lab for genomic sequencing
(Foundation Medicine). The details of sample requirement,
DNA extraction and NGS were described previously; most
samples represent advanced disease32 Targeted exons of 182
or 236 cancer-related genes and introns of 14 or 19 genes
frequently rearranged in cancer were sequenced
(Supplemental Table 1A and 1B) (Overall, 2974 cases were
sequenced on the 182 gene panel and 1890 cases on the 236
gene panel.)
Average depth of sequencing was greater than 250x, with
100x at > 99% of exons. This method of sequencing enabled to
detect copy number changes, gene rearrangement, and single
nucleotide variants with 99% specificity and 99% sensitivity
for base substitution, and 95% sensitivity for copy number
changes. Amplification was defined as copy number increase
of ≥ 8 copies (equivocal, 6 to 7 copies). Sequencing data was
analyzed with a customized analysis pipeline described
previously32 Clinical interpretation of genetic alterations
were provided by N-of-One (https://n-of-one.com)
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